(Q43246296)

17 November 2017

title

Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine (English)

1 reference

17 November 2017

1 reference

6

1 reference

17 November 2017

1

Nora M Hagelberg

1 reference

17 November 2017

Marko A Peltoniemi

2

1 reference

17 November 2017

Teijo I Saari

3

1 reference

17 November 2017

Kaisa J Kurkinen

4

1 reference

17 November 2017

Kari Laine

5

1 reference

17 November 2017

Klaus T Olkkola

7

1 reference

17 November 2017

publication date

7 November 2009

1 reference

17 November 2017

published in

European Journal of Pain

1 reference

17 November 2017

volume

14

1 reference

17 November 2017

issue

6

1 reference

17 November 2017

page(s)

625-629

1 reference

Effect of racemic mixture and the (S+)-isomer of ketamine on temporal and spatial summation of pain.

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Ketamine for chronic non-cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Peri-operative ketamine for acute post-operative pain: a quantitative and qualitative systematic review (Cochrane review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Side effects of ketamine in the long-term treatment of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Relief of glossopharyngeal neuralgia by ketamine-induced N-methyl-aspartate receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Short- and long-term efficacy of oral ketamine in eight chronic-pain patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Pharmacokinetics and analgesic effects of i.m. and oral ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

N of 1 randomised controlled trials of oral ketamine in patients with chronic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Measurement of Recovery from Outpatient General Anaesthesia with a Simple Ocular Test

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Morphine and ibuprofen compared using the cold pressor test

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Effects of enzyme induction, renal and cardiac function on ketamine plasma kinetics in patients with ketamine long-term analgosedation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Managing chronic whiplash associated pain with a combination of low-dose opioid (remifentanil) and NMDA-antagonist (ketamine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Ketamine spares morphine consumption after transthoracic lung and heart surgery without adverse hemodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Sensitive liquid chromatography-tandem mass spectrometry method for the determination of clarithromycin in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

The synergistic effect of combined treatment with systemic ketamine and morphine on experimentally induced windup-like pain in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Pencil and paper tests-sensitivity to psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Treatment of central post-stroke pain with oral ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Oral ketamine for the treatment of type I complex regional pain syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.10.003

10.1016/J.EJPAIN.2009.10.003

21 January 2018

Identifiers

DOI

1 reference

17 November 2017

1 reference